# The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin

> **NCT02597309** · PHASE4 · WITHDRAWN · sponsor: **Joslin Diabetes Center**

## Conditions studied

- Diabetes, Obesity

## Interventions

- **DRUG:** Canagliflozin

## Key facts

- **NCT ID:** NCT02597309
- **Lead sponsor:** Joslin Diabetes Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-11
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597309, "The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02597309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*